Sigma Planning Corp
ESPR icon

Sigma Planning Corp’s Esperion Therapeutics ESPR Stock Holding History

Sigma Planning Corp’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,250
Closed -$17.6K – 1269
2025
Q1 		$17.6K Sell
12,250
-178,191
-94% -$328K ﹤0.01% 1195
2024
Q4 		$419K Buy
190,441
+178,200
+1,456% +$416K 0.01% 808
2024
Q3 		$20.2K Buy
12,241
+100
+0.8% +$202 ﹤0.01% 1200
2024
Q2 		$27K Buy
+12,141
New +$28.6K ﹤0.01% 1166

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Sigma Planning Corp's ESPR Position: Q2 2025 in Review

Sigma Planning Corp sold out of Esperion Therapeutics (ESPR) in Q2 2025, closing a stake of 12,250 shares — an estimated $17.6K sold.

Sigma Planning Corp first reported a position in ESPR in Q2 2024 and held it in 4 quarters. The position peaked at $419K in Q4 2024. 164 funds tracked by Wall St. Rank hold ESPR as of Q2 2025.

  • Sigma Planning Corp reported no remaining Esperion Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sigma Planning Corp sold 12,250 Esperion Therapeutics shares in Q2 2025, an estimated $17.6K.
  • Sigma Planning Corp first reported a position in Esperion Therapeutics in Q2 2024 and held it in 4 quarters.
  • Sigma Planning Corp's Esperion Therapeutics position peaked at $419K in Q4 2024.
  • 164 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2025.

Based on Sigma Planning Corp's 13F filing for Q2 2025, filed 5 Aug 2025.